Home versus outpatient pulmonary rehabilitation in COPD: a propensity-matched cohort study

Home-based exercise has been proposed as an equivalent treatment strategy to supervised outpatient pulmonary rehabilitation (PR), but it is not known whether its implementation into clinical practice produces similar benefits to those observed in trials. We compared the real-world responses of 154 patients with COPD undergoing home-based exercise with a matched group attending supervised PR. We observed smaller improvements in exercise capacity with home-based exercise compared with PR, but similar improvements in quality of life. We propose that supervised PR remains the standard of care, with home-based exercise a less effective alternative for those unable to attend PR.

Download Full-text

Effectiveness of a home-based pulmonary rehabilitation programme in pulmonary function and health related quality of life for patients with pulmonary tuberculosis: a pilot study

African Health Sciences ◽

10.4314/ahs.v14i4.14 ◽

2015 ◽

Vol 14 (4) ◽

pp. 866 ◽

Cited By ~ 13

Author(s):

D De Grass ◽

S Manie ◽

SL Amosum

Keyword(s):

Quality Of Life ◽

Pilot Study ◽

Pulmonary Tuberculosis ◽

Pulmonary Rehabilitation ◽

Health Related Quality ◽

Home Based ◽

Related Quality ◽

Health Related ◽

Pulmonary Rehabilitation Programme

Download Full-text

Quality of life before and after sinonasal surgery: a population-based matched cohort study

European Archives of Oto-Rhino-Laryngology ◽

10.1007/s00405-016-4272-2 ◽

2016 ◽

Vol 274 (2) ◽

pp. 795-802 ◽

Cited By ~ 7

Author(s):

Antti I. Alakärppä ◽

Timo J. Koskenkorva ◽

Petri T. Koivunen ◽

Olli-Pekka Alho

Keyword(s):

Quality Of Life ◽

Cohort Study ◽

Population Based ◽

Matched Cohort ◽

Matched Cohort Study ◽

Before And After

Download Full-text

Effectiveness of dienogest in improving quality of life in Asian women with endometriosis (ENVISIOeN): interim results from a prospective cohort study under real-life clinical practice

BMC Women s Health ◽

10.1186/s12905-019-0758-6 ◽

2019 ◽

Vol 19 (1) ◽

Cited By ~ 4

Author(s):

Kitirat Techatraisak ◽

Andon Hestiantoro ◽

Soon Ruey ◽

Maria Jesusa Banal-Silao ◽

Mee-Ran Kim ◽

...

Keyword(s):

Quality Of Life ◽

Cohort Study ◽

Clinical Practice ◽

Prospective Cohort Study ◽

Prospective Cohort ◽

Real Life ◽

Asian Women

Download Full-text

Health-related quality of life (QoL) in patients with advanced melanoma receiving immunotherapies in real-world clinical practice settings

Quality of Life Research ◽

10.1007/s11136-020-02520-7 ◽

2020 ◽

Vol 29 (10) ◽

pp. 2651-2660

Author(s):

Richard W. Joseph ◽

Frank Xiaoqing Liu ◽

Alicia C. Shillington ◽

Cynthia P. Macahilig ◽

Scott J. Diede ◽

...

Keyword(s):

Quality Of Life ◽

Clinical Practice ◽

Real World ◽

Repeated Measures ◽

Advanced Melanoma ◽

Health Related Quality ◽

Related Quality ◽

Health Related ◽

Eq Vas

Abstract Background Pembrolizumab (PEMBRO) and ipilimumab + nivolumab (IPI + NIVO) are approved advanced melanoma (AM) immunotherapies. To address limited health-related quality of life (QoL) real-world evidence with immunotherapies in AM, we compared QoL in AM patients receiving either treatment in clinical practice. Methods A prospective US observational study enrolled adult AM patients initiating first-line PEMBRO or IPI + NIVO between June 2017 and March 2018. Endpoints included the QLQ-C30 global health score (GHS) and EuroQol visual analog scale (EQ-VAS) scores. Mean changes were compared using repeated measures mixed-effects models and are presented covariate adjusted. Results 225 PEMBRO and 187 IPI + NIVO patients were enrolled. From baseline through week 24, PEMBRO was associated with 3.2 mean GHS score increase (95% CI 0.5, 5.9; p = .02), while no change was observed with IPI + NIVO; 0.2 (95% CI − 2.6, 3.0; p = 0.87). Among objective treatment-responders, GHS scores associated with PEMBRO increased 6.0 (95% CI 3.1, 8.8; p < .0001); IPI + NIVO patients increased 3.8 (95% CI 0.8, 6.9; p = .01). In treatment non-responders, IPI + NIVO was associated with GHS/QoL deterioration of − 3.7 (95% CI − 6.8, − 0.6; p = .02), PEMBRO non-responders demonstrated no change; 0.7 (95% CI − 2.3, 3.7; p = 0.6). Between treatments, PEMBRO patients increased 2.6 greater in EQ-VAS (95% CI 0.6, 4.5; p = .01) vs IPI + NIVO at 24 weeks. Conclusions PEMBRO was associated with better 24-week QoL compared to IPI + NIVO in actual clinical practice settings. Real-world data has known limitations, but with further confirmation these results may have implications for treatment selection.

Download Full-text